Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 7,035 shares, a decrease of 38.1% from the December 31st total of 11,368 shares. Based on an average daily volume of 19,600 shares, the short-interest ratio is presently 0.4 days. Based on an average daily volume of 19,600 shares, the short-interest ratio is presently 0.4 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix at the end of the most recent quarter. Institutional investors and hedge funds own 11.84% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Pulmatrix Stock Down 1.9%

Shares of PULM traded down $0.05 during mid-day trading on Friday, hitting $2.57. The company’s stock had a trading volume of 6,450 shares, compared to its average volume of 13,454. The stock’s 50-day moving average is $3.13 and its two-hundred day moving average is $4.32. Pulmatrix has a one year low of $2.15 and a one year high of $10.40.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).